Igrene (ABI) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
16 Jan, 2026Executive summary
Focus on developing technology to convert leaking biogenic methane in Siljansringen into hydrogen and carbon using energy-efficient, CO2-free cold pyrolysis in partnership with SEID AS.
No revenues reported for the quarter; operations are pre-commercial and focused on R&D and demonstration projects.
Strategic shift driven by Swedish legal restrictions on natural gas extraction, with emphasis on environmental benefits and market potential for hydrogen and carbon.
Financial highlights
Operating result for the quarter: –1,748 KSEK (improved from –2,551 KSEK year-over-year).
Result after financial items: –1,663 KSEK (–2,551 KSEK year-over-year).
Earnings per share: –0.01 SEK (–0.02 SEK year-over-year).
No operating income; total costs for the quarter were 1,748 KSEK, mainly for ongoing operations.
Depreciation for the quarter: 0 KSEK (38 KSEK year-over-year).
Outlook and guidance
Awaiting potential legislative changes to allow methane extraction; current focus is on technology development and demonstration.
Market potential for both the technology and the end products (hydrogen and carbon) is considered significant, especially given the modularity and scalability of the process.
Latest events from Igrene
- Wider losses and zero revenue, but strengthened equity after rights issue; regulatory hurdles persist.ABI
Q4 202517 Oct 2025 - Regulatory setbacks halted project progress despite strong liquidity and high equity ratio.ABI
Q3 202518 Jul 2025 - Net loss increased, no dividend, and focus shifts to emission-free hydrogen and carbon projects.ABI
Q4 202413 Jun 2025 - Quarterly loss increased as Igrene advances emission-free hydrogen and carbon plans.ABI
Q3 202413 Jun 2025 - Losses increased and demo plant delayed, but equity and cash position strengthened.ABI
Q2 20256 Jun 2025 - Losses increased but cash strengthened after rights issue; focus on green hydrogen tech.ABI
Q1 20256 Jun 2025